LANCL2 and inflammatory bowel disease: The results in vivo demonstrated that the lead compound, NSC61610, engaged LANCL2 in an AC/cAMP-dependent manner in vitro and ameliorated experimental IBD by downmodulating colonic inflammatory gene expression and favoring Treg cell responses (73).